Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum

Pallavi Madhiraju- March 31, 2025 0

Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact. Read More

New hope for asthma and eczema? Akeso’s latest antibody AK139 enters clinical trials

Pallavi Madhiraju- February 14, 2025 0

Akeso, Inc. (9926.HK) has announced a major milestone with the acceptance of its Investigational New Drug (IND) application for AK139 by the China National Medical ... Read More

Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion

Pallavi Madhiraju- August 10, 2024 0

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More

How Johnson & Johnson’s billion-dollar bet on NM26 could transform atopic dermatitis treatment

Pallavi Madhiraju- July 12, 2024 0

Johnson & Johnson (NYSE: JNJ) has successfully concluded its acquisition of Yellow Jersey, a division previously part of Numab Therapeutics, for a substantial $1.25 billion. ... Read More

Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors

pharmanewsdaily- July 15, 2018 0

Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More